Anthrasil market report points to faster growth in Asia-Pacific

The Business Research Company says the Anthrasil market will be shaped by biodefense funding, stockpiling, and broader use of anthrax immune globulin therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Anthrasil is used to help treat inhalational anthrax, a rare but serious infection tied to biodefense and public health preparedness. - Rising anthrax cases and government stockpiling needs could keep demand for immune globulin therapies elevated.

What happened: - The Business Research Company released an Anthrasil market report on Oct. 29, 2026. - The report says North America held the largest Anthrasil market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period. - The company offered a free sample of the report and a full version of the report.

The details: - Anthrasil is an anthrax immune globulin derived from the plasma of people vaccinated against anthrax. - Anthrasil is used as an adjunct to antibiotics for inhalational anthrax in adults and children. - The therapy works by neutralizing anthrax toxins and reducing cellular damage. - Historical market growth was supported by government biodefense initiatives. - Clinical success with immune globulin therapies supported adoption when no alternative toxin neutralizers were available. - National emergency preparedness programs and crisis-time regulatory approvals also helped the market. - The report says future growth will be supported by public health preparedness funding, expanding biodefense stockpiles, rapid toxin-neutralization strategies, plasma-derived product processing improvements, and long-term government purchasing agreements. - The report says anthrax immune globulin use is becoming more widespread in the forecast period. - Combination treatment protocols are also expanding. - Strategic stockpiling of immune globulins is increasing. - The report highlights growing attention to anthrax management for both pediatric and adult patients. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The report ties market growth to a mix of public health risk and government procurement, not broad consumer demand. - The strongest long-term demand signal appears to come from preparedness spending and regional outbreak pressure. - A World Health Organization report in December 2023 cited suspected anthrax cases in Zambia rising from 42 between September 2022 and January 2023 to 684 by late November 2023, with four deaths. - That jump underscores why passive-immunity treatments remain relevant in outbreak response.

What's next: - The report expects sustained biodefense spending and stockpile expansion to remain the main market drivers through 2026. - Asia-Pacific will be the key region to watch for faster expansion as preparedness and treatment protocols evolve.